The Institute of Cancer Research, London, is one of the world’s most influential cancer research institutes, with an outstanding record of achievement dating back more than 100 years. We provided the first convincing evidence that DNA damage is the basic cause of cancer, laying the foundation for the now universally accepted idea that cancer is a genetic disease. Today, The Institute of Cancer Research (ICR) leads the world at isolating cancer-related genes and discovering new targeted drugs for personalised cancer treatment. Under the leadership of our Chief Executive, Professor Paul Workman FRS, the ICR is ranked as the UK’s leading academic research centre. Together with our partner The Royal Marsden, we are rated in the top four cancer centres globally. The ICR is committed to attracting, developing and retaining the best minds in the world to join us in our mission – to make the discoveries that defeat cancer. The Cancer Research UK Cancer Therapeutics Unit (CTU), within the Division of Cancer Therapeutics, is a multidisciplinary 'bench to bedside' centre, comprising around 160 staff dedicated to the discovery and development of novel therapeutics for the treatment of cancer. The Cancer Therapeutics Unit’s exciting goal is to discover high quality small molecule drug candidates and to progress these to clinical trial. All the scientific disciplines are in place to make this possible, including medicinal chemistry, biology, drug metabolism and clinical specialists who focus on new molecular targets emerging from human genome and ground breaking cell biology research.
A postdoctoral position is available in Dr Rob van Montfort’s Hit Discovery and Structural Design Team within the CTU. The Post-doc will be involved in high-throughput X-ray crystallography, fragment-based screening and structure-based drug design and will be responsible for protein expression, purification, crystallisation, structure determination and structural analysis of protein-ligand complexes from one of the CTU’s drug discovery programmes. The successful candidate will also be part of the Division of Structural Biology, in which the crystallographers in Dr van Montfort’s team are embedded, and will have access to state of the art crystallisation facilities, in-house X-ray sources and excellent access to synchrotrons. The successful candidate will interact closely with the biology, computational chemistry and medicinal chemistry teams at the CTU, and will therefore be expected to work across the two sites in Chelsea, London and Sutton, Surrey. Applicants must have a PhD in a biological or physical science, and experience in macromolecular crystallography (to include protein biochemistry, protein crystallisation, & protein crystallography). Experience in molecular biology, protein expression in insect cells, structure-based drug design, and/or biophysics will be an advantage. The starting salary will be in the range £29,960 to £36,830 p.a. inclusive (based on previous post-doctoral experience) and the post is offered on a fixed term contract of 2 years. Informal enquiries to rob.vanmontf...@icr.ac.uk<mailto:rob.vanmontf...@icr.ac.uk> or yann-vai.lebi...@icr.ac.uk<mailto:isaac.westw...@icr.ac.uk>. Closing date is July 9th 2017. Please DO NOT send your application to Dr van Montfort or Dr Le Bihan; CVs must be submitted in line with the instructions below. Dr. Rob van Montfort Team Leader Hit Discovery and Structural Design Joint Interim Head of Division of Structural Biology Divisions of Cancer Therapeutics and Structural Biology The Institute of Cancer Research 15 Cotswold Road Sutton SM2 5NG UK Tel: +44-(0)20-8722-4364 (Sutton) +44-(0)20-7153-5142 (Chelsea) Email: rob.vanmontf...@icr.ac.uk<mailto:rob.vanmontf...@icr.ac.uk> The Institute of Cancer Research: Royal Cancer Hospital, a charitable Company Limited by Guarantee, Registered in England under Company No. 534147 with its Registered Office at 123 Old Brompton Road, London SW7 3RP. This e-mail message is confidential and for use by the addressee only. If the message is received by anyone other than the addressee, please return the message to the sender by replying to it and then delete the message from your computer and network.
